ReviewPlant methods2019
Understanding glycaemic control and current approaches for screening antidiabetic natural products from evidence-based medicinal plants.
Review in Plant methods, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 146 citations in OpenAlex.
- Ethnopharmacological insights into type 2 diabetes management by traditional Moroccan herbal teas: HPLC-MS characterization of phenolic compounds and their related antioxidant and enzyme inhibitory activities.BMC complementary medicine and therapies · 2026Article
- Flavonoids and chalcones as selective α-glucosidase inhibitors: from enzymatic screening to validation using the human enzyme.RSC medicinal chemistry · 2026Article
- Phenolic Profile, Antioxidant Potential, and Antidiabetic Effects of Aristolochia longa Extracts in Streptozotocin-Induced Diabetic Rats.Chemistry & biodiversity · 2026Article
- The Application of Omics Technologies in Type II Diabetes Mellitus Research.Current diabetes reviews · 2026Review
- HPTLC based screening method for the evaluation of α-amylase inhibitory activity in edible flowers.Scientific reports · 2025Article
- Antidiabetic potentials of gypenosides: A review on the preclinical effects in glucose and insulin modulation as well as diabetes-related complications.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Multi-Target Modulation of Polyphenols in Diabetic Kidney Disease Therapeutics: A Comprehensive Review.Food science & nutrition · 2025Review
- Effects ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Lycopene ameliorates diabetes-induced pancreatic, hepatic, and renal damage by modulating the JAK/STAT/SOCS signaling pathway in rats.Iranian journal of basic medical sciences · 2025Article
- Structural Characterization and In Vitro and In Silico Studies on the Anti-Foods (Basel, Switzerland) · 2024Article
- Antidiabetic potential of fenugreek (Food science & nutrition · 2024Review
- The effect of myo-inositol supplementation on AMPK/PI3K/AKT pathway and insulin resistance in patients with NAFLD.Food science & nutrition · 2024Article
- Optimizing antidiabetic properties ofFood science & nutrition · 2024Article
- Synergistic anti-diabetic effect of phloroglucinol and total procyanidin dimer isolated from3 Biotech · 2024Article
- Article
- A comprehensiveFrontiers in pharmacology · 2024Review
- Review of dietary patterns and gastric cancer risk: epidemiology and biological evidence.Frontiers in oncology · 2024Review
- Review
- Article
- Algae-Derived Natural Products in Diabetes and Its Complications-Current Advances and Future Prospects.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 Diabetes Mellitus has reached epidemic proportions as a result of over-nutrition and increasingly sedentary lifestyles. Current therapies, although effective, are not without limitations. These limitations, the alarming increase in the prevalence of diabetes, and the soaring cost of managing diabetes and its complications underscores an urgent need for safer, more efficient and affordable alternative treatments. Over 1200 plant species are reported in ethnomedicine for treating diabetes and these represents an important and promising source for the identification of novel antidiabetic compounds. Evaluating medicinal plants for desirable bioactivity goes hand-in-hand with methods in analytical biochemistry for separating and identifying lead compounds. This review aims to provide a comprehensive summary of current methods used in antidiabetic plant research to form a useful resource for researchers beginning in the field. The review summarises the current understanding of blood glucose regulation and the general mechanisms of action of current antidiabetic medications, and combines knowledge on common experimental approaches for screening plant extracts for antidiabetic activity and currently available analytical methods and technologies for the separation and identification of bioactive natural products. Common in vivo animal models, in vitro models, in silico methods and biochemical assays used for testing the antidiabetic effects of plants are discussed with a particular emphasis on in vitro methods such as cell-based bioassays for screening insulin secretagogues and insulinomimetics. Enzyme inhibition assays and molecular docking are also highlighted. The role of metabolomics, metabolite profiling, and dereplication of data for the high-throughput discovery of novel antidiabetic agents is reviewed. Finally, this review also summarises sample preparation techniques such as liquid-liquid extraction, solid phase extraction, and supercritical fluid extraction, and the critical function of nuclear magnetic resonance and high resolution liquid chromatography-mass spectrometry for the dereplication, putative identification and structure elucidation of natural compounds from evidence-based medicinal plants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.